OR WAIT null SECS
CPI has revealed an agreement with DFE Pharma, making it the latest partner of the Medicines Manufacturing Innovation Centre (MMIC) collaboration.
In a June 10, 2021 press release, the Centre for Process Innovation (CPI) has revealed an agreement with DFE Pharma, making it the latest partner of the Medicines Manufacturing Innovation Centre (MMIC) collaboration.
Through the partnership, MMIC will draw upon DFE Pharma’s expertise in the development of excipients for oral solid-dosage medicines to help address key challenges currently facing the industry. More specifically, DFE Pharma will help to advance Phase 1 of the Grand Challenge 1, which aims to develop a novel digitally twinned continuous direct compression (CDC) platform to reduce waste and cut costs during the manufacture of oral dosage medicines.
“We are excited to be collaborating with global excipient manufacturer DFE Pharma; well-respected in the market for its excellence in particle technology and particle and process interactions,” said John Arthur, director of MMIC at CPI, in the press release. “This partnership will enable Phase 1 of Grand Challenge 1 to be delivered more quickly and cost-effectively.”
Bas van Driel, CEO at DFE Pharma, added, in the press release, “We are delighted to establish a closer relationship with the MMIC, the [United Kingdom’s] leading initiative to drive innovation in pharmaceutical manufacturing, to help ensure the success of Grand Challenge 1. This unique opportunity will allow us to work alongside and showcase our world-class capabilities in excipient development to the other partners.”